Indian pharmaceutical companies are drawing attention after reports suggested that the US FDA has approached Indian manufacturers to explore additional supplies of a key cancer treatment drug facing shortages in the United States. The medicine in focus is Ifosfamide, a chemotherapy drug used in the treatment of multiple cancers, including testicular, bladder and lung cancer. Supply disruptions and manufacturing challenges in the US have created concerns over availability. Business Today’s, Neetu Chandra Sharma, who closely tracks the pharmaceutical sector, highlighted that companies such as Cipla, Alkem and Zydus Lifesciences are being closely watched due to their strong compliance records, manufacturing capabilities and experience in regulated markets. While no specific orders have been confirmed yet, the development reinforces India's growing importance as a global supplier of critical medicines and oncology drugs.